These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12067785)

  • 1. Homoharringtonine effective in CML patients.
    Hitt E
    Lancet Oncol; 2002 May; 3(5):259. PubMed ID: 12067785
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Maiti A; Cortes J; Ferrajoli A; Estrov Z; Borthakur G; Garcia-Manero G; Jabbour E; Ravandi F; O'Brien S; Kantarjian H
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28278723
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
    O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
    Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
    Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
    Kantarjian HM; Giles FJ; O'Brien SM; Talpaz M
    Hematol Oncol Clin North Am; 1998 Feb; 12(1):31-80. PubMed ID: 9523225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.
    Zhu J; Ding B; Li Y
    Leuk Lymphoma; 2013 Jul; 54(7):1426-9. PubMed ID: 23270584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
    O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
    Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
    Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
    Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
    de Lavallade H; Khorashad JS; Davis HP; Milojkovic D; Kaeda JS; Goldman JM; Apperley JF; Marin D
    Blood; 2007 Oct; 110(7):2779-80. PubMed ID: 17881650
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.
    Mahadeo KM; Cole PD
    Blood; 2010 May; 115(18):3852. PubMed ID: 20448119
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
    Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
    Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
    Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).
    Simonsson B; Kloke O; Stahel RA;
    Ann Oncol; 2005; 16 Suppl 1():i52-3. PubMed ID: 15888754
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic myelogenous leukemia: a review.
    Cortes JE; Talpaz M; Kantarjian H
    Am J Med; 1996 May; 100(5):555-70. PubMed ID: 8644769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of myelogenous leukemia: current status and investigational options.
    Kantarjian HM; O'Brien S; Anderlini P; Talpaz M
    Blood; 1996 Apr; 87(8):3069-81. PubMed ID: 8605319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.